It is a glucagon-like peptide-1 (GLP-1) receptor agonist that helps to lower blood sugar levels by increasing insulin secretion, decreasing glucagon secretion, and slowing gastric emptying
Abstract Obesity rates, once thought to be on an inevitable rise with limited treatment options, have recently stabilized and begun to decline in the US, a trend that coincides with the increased use of GLP-1 receptor agonist medications for weight management
The compound then received GRAS (Generally Recognized as Safe) designation from the FDA for use as a food ingredient, which is a separate regulatory category from drug approval
Since these medications work in different ways and target different systems in the body, they generally do not interfere with each other directly
Through this mechanism of action, semaglutide minimizes cravings and makes it easier to avoid overeating and practice portion control
Table of Contents Why patients are turning to compounded GLP-1 therapies Understanding the safety concerns of compounded GLP-1 products How to evaluate patients taking compounded GLP-1 medications Documentation, counseling, and transitioning to FDA-approved therapy Frequently Asked Questions Why Patients Are Turning to Compounded GLP-1 Therapies Several factors have fueled the rapid growth of compounded GLP-1 therapies